Exhibit 99.1

 

 

BIOLASE REPORTS 2019 FOURTH QUARTER; NET REVENUE INCREASED 18% SEQUENTIALLY

Full Year Gross Margin Increased by 120 Basis Points Year Over Year

Fourth Quarter Operating Loss Improves by $3.5 Million Year Over Year

Conference Call Today at 4:30pm ET

IRVINE, Calif., March 26, 2020 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today reported net revenue of $10.2 million and $37.8 million for the fourth quarter and year ended December 31, 2019, respectively.

Sequential Fourth Quarter Results Demonstrate Sequential Operating Momentum

 

Net revenue increased 18% sequentially

 

U.S. laser revenue increased 44% sequentially

 

International laser revenue increased 2% sequentially

 

Worldwide consumables and other revenue increased 1% sequentially

 

GAAP net loss decreased 48% year over year to $3.6 million

 

Adjusted EBITDA loss decreased 39% year over year to $1.6 million

 

Epic Hygiene laser for dental hygienists received FDA clearance in U.S.

 

“We made significant progress in 2019 as we continued to transition BIOLASE from an R&D-centric company into a commercially-focused business,” commented Todd Norbe, President and Chief Executive Officer.  “I believe the sequential improvement in the fourth quarter demonstrates the early success of our go-to-market strategy, under which we continue to rationalize our cost structure and rebuild our salesforce into a more disciplined customer-centric organization that is beginning to create positive change. I believe we have the right leadership team in place to achieve our growth and profitability objectives going forward.

 

“In December 2019, we received FDA clearance for our Epic Hygiene laser for dental hygienists, representing the achievement of another significant regulatory milestone, and just this week we received FDA clearance for LBR (laser bacterial reduction). This new laser system provides dental professionals a total solution to effectively manage non-surgical periodontitis. Our goal is to expand the reach of this great technology through increased awareness and improved sales and marketing execution.  

 


Lastly, I want to acknowledge the impact of the coronavirus pandemic and express our heartfelt concern to those who have been impacted. The safety of our employees, customers, partners and patients is paramount and we are taking every precaution to ensure their well-being during this difficult period as we face COVID-19. While it’s our hope that this situation is controlled as soon as possible, the matter remains very fluid and it’s difficult to predict when commercial activities, and more specifically, the dental market will return to normal levels. Given the recent dental office closures worldwide, we expect our first quarter 2020 sales to be down significantly year over year. Prior to the coronavirus pandemic we felt strongly that having filled almost all of our open U.S. sales territories would lead to year over year revenue improvement for the last three quarters of 2020, however, whether we can achieve this now depends on how quickly our U.S. and international business returns to some level of normalcy.”  

 

2019 Fourth Quarter Financial Results

Net revenue for the fourth quarter of 2019 was $10.2 million, up 18% from the third quarter of 2019, and down 22% year over year compared to net revenue of $13.0 million for the fourth quarter of 2018. U.S. laser revenue was $3.3 million for the fourth quarter of 2019, up 43% from the third quarter of 2019, and down 41% compared to U.S. laser revenue of $5.6 million for the fourth quarter of 2018. U.S. consumables and other revenue for the fourth quarter of 2019, which consists of revenue from consumable products such as disposable tips, was down 3% compared to the third quarter of 2019 and down 29% year over year compared to the fourth quarter of 2018. International laser revenue increased to $3.5 million for the fourth quarter of 2019, up 2% both compared to the third quarter of 2019 $3.4 million for the fourth quarter of 2018.

 

Gross margin for the fourth quarter of 2019 was 43%, the same as for the fourth quarter of 2018, despite lower revenue. Total operating expenses were $7.5 million for the fourth quarter of 2019 compared to $12.1 million for the fourth quarter of 2018, a decrease of $4.7 million or 39% year over year. Operating loss for the fourth quarter of 2019 was $3.0 million, compared to an operating loss of $6.5 million for the fourth quarter of 2018, a decrease of $3.5 million year over year. The net loss for the fourth quarter of 2019 was $3.6 million, or $0.13 per share, compared to a net loss of $6.9 million, or $0.33 per share, for the fourth quarter of 2018.

For the fourth quarter of 2019, the Company had a $1.6 million, or $0.05 per share, Adjusted EBITDA loss compared with an Adjusted EBITDA loss of $2.7 million, or $0.13 per share, for the fourth quarter of 2018. A reconciliation of GAAP net loss to Adjusted EBITDA on an aggregate and a per share basis is at the end of this news release.

 

Cash, cash equivalents, and restricted cash totaled $6.1 million as of December 31, 2019.

 

Full Year 2019 Financial Results

 

Net revenue for the year ended December 31, 2019 was $37.8 million, a decrease of 18% compared to net revenue of $46.2 million for the year ended December 31, 2018. U.S. laser revenue was $11.1 million for the year ended December 31, 2019, a decrease of 28% compared to U.S. laser revenue of $15.5 million for the year ended December 31, 2018. U.S. consumables and other revenue for the year ended December 31, 2019, which consists of revenue from consumable products such as disposable tips, decreased 11% year over year. International laser revenue decreased to $11.7 million for the year ended December 31, 2019 compared to $14.2 million for the year ended December 31, 2018.

 


Gross margin for the year ended December 31, 2019 was 38% compared to 37% for the year ended December 31, 2018. Total operating expenses were $29.9 million for the year ended December 31, 2019 compared to $37.8 million for the year ended December 31, 2018, a decrease of $7.9 million year over year. Operating loss for the year ended December 31, 2019 was $15.6 million, compared to an operating loss of $20.9 million for the year ended December 31, 2018, a decrease of $5.3 million year over year. The net loss for the year ended December 31, 2019 was $17.9 million, or $0.77 per share compared to a net loss of $21.5 million, or $1.05 per share for the year ended December 31, 2018.

Adjusted EBITDA for the year ended December 31, 2019 was a loss of $10.4 million, or $0.44 per share compared with an Adjusted EBITDA loss of $14.5 million, or $0.71 per share for the year ended December 31, 2018.

 

Conference Call Information

BIOLASE, Inc. will host a conference call March 26, 2019 at 4:30 p.m. Eastern Time to discuss its operating results for the fourth quarter and full year ended December 31, 2019 and to discuss the expected impact of the COVID-19 pandemic on BIOLASE’s business. For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 800-353-6461. For international participants outside the U.S./Canada, the dial-in number is 334-323-0501. For all callers, refer to the Conference ID 7830999. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see “Investor Events”.

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately patented 208 and 56 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold over 41,000 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.


BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the go-to-market sales strategy and anticipated sales during the first quarter of 2020. Forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

BIOLASE, Inc.

John R. Beaver, Executive Vice President and Chief Financial Officer

833-BIOLASE

jbeaver@biolase.com

or

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

 

 

Tables Follow


 

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

(Unaudited)

 

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Net revenue

 

$

 

10,182

 

 

$

 

13,045

 

 

$

 

37,799

 

 

$

 

46,155

 

Cost of revenue

 

 

 

5,765

 

 

 

 

7,432

 

 

 

 

23,511

 

 

 

 

29,260

 

Gross profit

 

 

 

4,417

 

 

 

 

5,613

 

 

 

 

14,288

 

 

 

 

16,895

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

 

3,731

 

 

 

 

5,084

 

 

 

 

14,396

 

 

 

 

18,121

 

General and administrative

 

 

 

2,634

 

 

 

 

3,080

 

 

 

 

10,748

 

 

 

 

11,771

 

Engineering and development

 

 

 

1,100

 

 

 

 

1,276

 

 

 

 

4,765

 

 

 

 

5,203

 

Disposal of internally developed software

 

 

 

 

 

 

 

1,185

 

 

 

 

 

 

 

 

1,185

 

Loss on patent litigation settlement

 

 

 

 

 

 

 

1,500

 

 

 

 

 

 

 

 

1,500

 

Total operating expenses

 

 

 

7,465

 

 

 

 

12,125

 

 

 

 

29,909

 

 

 

 

37,780

 

Loss from operations

 

 

 

(3,048

)

 

 

 

(6,512

)

 

 

 

(15,621

)

 

 

 

(20,885

)

Loss on foreign currency transactions

 

 

 

33

 

 

 

 

5

 

 

 

 

121

 

 

 

 

58

 

Interest expense, net

 

 

 

598

 

 

 

 

430

 

 

 

 

2,157

 

 

 

 

510

 

Non-operating loss

 

 

 

631

 

 

 

 

435

 

 

 

 

2,278

 

 

 

 

568

 

Loss before income tax provision

 

 

 

(3,679

)

 

 

 

(6,947

)

 

 

 

(17,899

)

 

 

 

(21,453

)

Income tax provision (benefit)

 

 

 

(111

)

 

 

 

(28

)

 

 

 

(44

)

 

 

 

63

 

Net loss

 

$

 

(3,568

)

 

$

 

(6,919

)

 

$

 

(17,855

)

 

$

 

(21,516

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Deemed dividend on convertible preferred stock:

 

$

 

 

 

$

 

 

 

$

 

 

 

$

 

 

Net loss per share attributable to common stockholders:

 

$

 

(3,568

)

 

$

 

(6,919

)

 

$

 

(17,855

)

 

$

 

(21,516

)

Basic

 

$

 

(0.13

)

 

$

 

(0.33

)

 

$

 

(0.77

)

 

$

 

(1.05

)

Diluted

 

$

 

(0.13

)

 

$

 

(0.33

)

 

$

 

(0.77

)

 

$

 

(1.05

)

Shares used in the calculation of net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

28,118

 

 

 

 

20,732

 

 

 

 

23,202

 

 

 

 

20,588

 

Diluted

 

 

 

28,118

 

 

 

 

20,732

 

 

 

 

23,202

 

 

 

 

20,588

 


 

BIOLASE, INC.

 

CONSOLIDATED BALANCE SHEETS

 

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

 

(unaudited)

 

 

(unaudited)

 

ASSETS

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

5,789

 

 

$

 

8,044

 

Restricted cash

 

 

 

312

 

 

 

 

312

 

Accounts receivable, less allowance of $2,531 and $850 in 2019

   and 2018, respectively

 

 

 

8,760

 

 

 

 

11,112

 

Inventory

 

 

 

10,995

 

 

 

 

12,248

 

Prepaid expenses and other current assets

 

 

 

1,163

 

 

 

 

1,591

 

Total current assets

 

 

 

27,019

 

 

 

 

33,307

 

Property, plant and equipment, net

 

 

 

1,193

 

 

 

 

1,975

 

Goodwill

 

 

 

2,926

 

 

 

 

2,926

 

Right of use asset

 

 

 

276

 

 

 

 

 

Other assets

 

 

 

433

 

 

 

 

308

 

Total assets

 

$

 

31,847

 

 

$

 

38,516

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

 

5,332

 

 

$

 

5,953

 

Accrued liabilities

 

 

 

4,744

 

 

 

 

7,538

 

Deferred revenue

 

 

 

2,237

 

 

 

 

2,476

 

Term loan

 

 

 

13,466

 

 

 

 

 

Total current liabilities

 

 

 

25,779

 

 

 

 

15,967

 

Deferred income taxes, net

 

 

 

78

 

 

 

 

77

 

Deferred revenue, noncurrent

 

 

 

358

 

 

 

 

 

Warranty accrual, noncurrent

 

 

 

245

 

 

 

 

447

 

Other liabilities

 

 

 

1,045

 

 

 

 

100

 

Term loan

 

 

 

 

 

 

 

10,836

 

Total liabilities

 

 

 

27,505

 

 

 

 

27,427

 

Redeemable preferred stock:

 

 

 

 

 

 

 

 

 

 

Preferred stock, par value $0.001 per share

 

$

 

3,965

 

 

$

 

 

Total redeemable preferred stock

 

 

 

3,965

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

Common stock, par value $0.001 per share

 

 

 

31

 

 

 

 

21

 

Additional paid-in capital

 

 

 

235,594

 

 

 

 

228,430

 

Accumulated other comprehensive loss

 

 

 

(701

)

 

 

 

(670

)

Accumulated deficit

 

 

 

(234,547

)

 

 

 

(216,692

)

Total stockholders’ equity

 

 

 

377

 

 

 

 

11,089

 

Total liabilities, redeemable preferred stock and

   stockholders’ equity

 

$

 

31,847

 

 

$

 

38,516

 


 

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited, in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Twelve Months Ended

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(17,855

)

 

$

(21,516

)

Adjustments to reconcile net loss to net cash and cash equivalents

   used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

982

 

 

 

945

 

Loss on disposal of assets

 

 

 

 

 

1,228

 

Provision for bad debts

 

 

1,695

 

 

 

469

 

Provision for inventory excess and obsolescence

 

 

413

 

 

 

166

 

Amortization of debt discounts

 

 

140

 

 

 

202

 

Amortization of debt issuance costs

 

 

188

 

 

 

126

 

Stock-based compensation

 

 

2,742

 

 

 

2,768

 

Warrants issued to consultants

 

 

48

 

 

 

 

Loss on patent litigation settlement

 

 

 

 

 

1,500

 

Deferred income taxes

 

 

7

 

 

 

(27

)

Earned interest income, net

 

 

2

 

 

 

1

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

655

 

 

 

(1,458

)

Inventory

 

 

840

 

 

 

(127

)

Prepaid expenses and other current assets

 

 

439

 

 

 

(25

)

Accounts payable and accrued liabilities

 

 

(3,156

)

 

 

1,762

 

Deferred revenue

 

 

114

 

 

 

(161

)

Net cash and cash equivalents used in operating activities

 

 

(12,746

)

 

 

(14,147

)

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

(207

)

 

 

(558

)

Proceeds from disposal of property, plant, and equipment

 

 

 

 

 

36

 

Net cash and cash equivalents used in investing activities

 

 

(207

)

 

 

(522

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Principal payments under capital lease obligation

 

 

 

 

 

(46

)

Borrowings under lines of credit

 

 

 

 

 

3,696

 

Payments under line of credit

 

 

 

 

 

(3,696

)

Borrowings under term loan

 

 

2,500

 

 

 

12,500

 

Payments of debt issuance costs

 

 

(133

)

 

 

(1,058

)

Proceeds from equity offering costs, net of expenses

 

 

9,171

 

 

 

 

Payments of equity offering costs

 

 

(821

)

 

 

(164

)

Proceeds from exercise of stock options

 

 

4

 

 

 

3

 

Net cash and cash equivalents provided by financing activities

 

 

10,721

 

 

 

11,235

 

Effect of exchange rate changes

 

 

(23

)

 

 

(106

)

Decrease in cash, cash equivalents and restricted cash

 

 

(2,255

)

 

 

(3,540

)

Cash, cash equivalents and restricted cash, beginning of period

 

 

8,356

 

 

 

11,896

 

Cash, cash equivalents and restricted cash, end of period

 

$

6,101

 

 

$

8,356

 

Supplemental cash flow disclosure - cash paid

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

1,784

 

 

$

23

 

Cash paid for income taxes

 

$

35

 

 

$

44

 

Cash paid for operating leases

 

$

797

 

 

$

 

Supplemental cash flow disclosure - non cash

 

 

 

 

 

 

 

 

Non-cash accrual for capital expenditures

 

$

18

 

 

$

31

 

Non-cash accrual for equity offering costs

 

$

129

 

 

$

 

Non-cash right-of-use assets obtained in exchange for lease obligation

 

$

276

 

 

$

 

Loss on patent litigation settlement

 

$

 

 

$

1,500

 

Settlement of liability awards

 

$

201

 

 

$

 

Warrants issued in connection with debt instruments

 

$

161

 

 

$

847

 


Non-GAAP Disclosure

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents. In 2019, the Company revised its non-GAAP financial measures to include the change in allowance for doubtful accounts in an effort to better align its Adjusted EBITDA with our loan covenants and how management evaluates business performance. Prior year non-GAAP disclosures have been revised to conform to the current definition of Adjusted EBITDA.

Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation and allowance for doubtful accounts. Management uses adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.


 

BIOLASE, INC.

 

Reconciliation of GAAP Net Loss to Adjusted EBITDA

 

(Unaudited)

 

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

GAAP net loss attributable to common stockholders

 

$

 

(3,568

)

 

$

 

(6,919

)

 

$

 

(17,855

)

 

$

 

(21,516

)

Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss

 

$

 

(3,568

)

 

$

 

(6,919

)

 

$

 

(17,855

)

 

$

 

(21,516

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

 

598

 

 

 

 

430

 

 

 

 

2,157

 

 

 

 

510

 

Income tax provision (benefit)

 

 

 

(111

)

 

 

 

(28

)

 

 

 

(44

)

 

 

 

63

 

Depreciation and amortization

 

 

 

215

 

 

 

 

233

 

 

 

 

969

 

 

 

 

945

 

Change in allowance for doubtful accounts

 

 

 

452

 

 

 

 

 

 

 

 

1,681

 

 

 

 

 

Disposal of internally developed software

 

 

 

 

 

 

 

1,185

 

 

 

 

 

 

 

 

1,185

 

Loss on patent litigation

 

 

 

 

 

 

 

1,500

 

 

 

 

 

 

 

 

1,500

 

Stock-based compensation

 

 

 

769

 

 

 

 

906

 

 

 

 

2,742

 

 

 

 

2,768

 

Adjusted EBITDA

 

$

 

(1,645

)

 

$

 

(2,693

)

 

$

 

(10,350

)

 

$

 

(14,545

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss attributable to common stockholders

   per share, basic and diluted

 

$

 

(0.13

)

 

$

 

(0.33

)

 

$

 

(0.77

)

 

$

 

(1.05

)

Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss per share, basic and diluted

 

$

 

(0.13

)

 

$

 

(0.33

)

 

$

 

(0.77

)

 

$

 

(1.05

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

 

0.02

 

 

 

 

0.02

 

 

 

 

0.09

 

 

 

 

0.02

 

Income tax provision (benefit)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

 

0.01

 

 

 

 

0.01

 

 

 

 

0.04

 

 

 

 

0.05

 

Change in allowance for doubtful accounts

 

 

 

0.02

 

 

 

 

 

 

 

 

0.07

 

 

 

 

 

Disposal of internally developed software

 

 

 

 

 

 

 

0.06

 

 

 

 

 

 

 

 

0.06

 

Loss on patent litigation

 

 

 

 

 

 

 

0.07

 

 

 

 

 

 

 

 

0.07

 

Stock-based compensation

 

 

 

0.03

 

 

 

 

0.04

 

 

 

 

0.12

 

 

 

 

0.13

 

Adjusted EBITDA, basic and diluted

 

$

 

(0.05

)

 

$

 

(0.13

)

 

$

 

(0.44

)

 

$

 

(0.71

)

 

View differences made from one to another to evaluate Biolase, Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biolase, Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account